HomeStocks
AYA
Artrya Ltd
Director Trades
| Date | Director | Value |
|---|
Company News
Biotechnology
Artrya Secures Second US Commercial Order for Salix SaaS Platform to Manage Coronary Artery Disease
Artrya (ASX: AYA) has signed a commercial agreement with US-based Northeast Georgia Health System for the use of its Salix AI cloud platform for point-of-care assessment and management of coronary artery disease.
Biotechnology
Artrya Wins FDA Clearance to Advance Rollout of Salix Coronary Plaque Module
Artrya (ASX: AYA) has received clearance from the US Food and Drug Administration for its Salix Coronary Plaque module. The regulatory milestone enables the company to charge per-scan fees in its largest market, significantly enhancing revenue potential. The approval follows Artrya’s recent US launch and builds on momentum established with its Salix Coronary Anatomy platform. […]
Company Videos
No videos found.